Metabolic Profile of Nebivolol, a Beta-adrenoceptor Antagonist with Unique Characteristics.
From: Department of Medical and Surgical Sciences, Clinica Medica, University of Brescia, Brescia, Italy. agabiti@med.unibs.it
Drugs
- Publish Date: 2007
- ISSN: 0012-6667
- Volume: 67
- Issue: 8
- Pages: 1097-107
- Medium: Print
- Language: English
- Citation (JAMA): Agabiti Rosei Enrico, Rizzoni Damiano, et al. Metabolic Profile of Nebivolol, a Beta-adrenoceptor Antagonist with Unique Characteristics.. Drugs 2007;67:1097-107
Abstract
beta-Adrenoceptor antagonists (beta-blockers) have historically been considered an effective and safe option for first-line treatment of hypertension. However, very recently, it has been proposed that beta-blockers should no longer be considered suitable for first-line therapy in the patient with uncomplicated hypertension because of unfavourable morbidity and mortality data. New evidence from recent clinical studies of nebivolol, a third-generation highly selective beta(1)-blocker with additional endothelial nitric oxide (NO)-mediated vasodilating activity, confirms previous findings that this drug differs from other beta-blockers. The combined mechanisms of beta-adrenoceptor antagonism and NO-mediated vasodilation may potentiate the blood pressure-lowering effect of this agent, and confer a broader favourable metabolic profile, which may be clinically relevant for hypertensive patients. The antioxidant properties of nebivolol and its neutral or even favourable effects on both carbohydrate and lipid metabolism are well documented. These properties consistently differentiate nebivolol from nonvasodilating beta-blockers such as atenolol, metoprolol or bisoprolol. Therapeutic indications for beta-blockers include a wide range of co-morbidities found in hypertensive patients, including ischaemic heart disease, tachyarrhythmias and heart failure. Given that the majority of hypertensive patients require more than one drug to control blood pressure, the multiple mechanisms of action and favourable metabolic profile of nebivolol could make it an alternative therapeutic option for hypertensive patients requiring beta-adrenoceptor therapy.
Mesh Headings (Keywords): Adrenergic beta-Antagonists, Antihypertensive Agents, Antioxidants, Benzopyrans, Blood Glucose, Cholesterol, Clinical Trials as Topic, Diabetes Mellitus, Dyslipidemias, Endothelium, Vascular, Ethanolamines, Heart Failure, Humans, Hypertension, Lipids, Nitric Oxide, Oxidative Stress, Vasodilation
Check for Full Text / PubMed Unique Identifier (PMID): 17521213
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.